In a deal that could result in $1.2 billion in milestone payments - on top of a $35 million up-front payment - EPIX Pharmaceuticals Inc. signed with GlaxoSmithKline plc to discover, develop and market drugs that target four G-protein-coupled receptors. (BioWorld Today)

Halozyme Therapeutics Inc.'s stock surged 59.2 percent Wednesday following news of an Enhanze technology licensing deal with F. Hoffmann-La Roche Ltd. worth up to $612 million plus royalties. (BioWorld Today)

Talks of an additional trial for the parathyroid hormone nasal spray (PTH1-34) to treat osteoporosis led Nastech Pharmaceutical Co. Inc. and Procter & Gamble Pharmaceuticals Inc. to amend their 10-month-old agreement - meaning Nastech will not receive $15 million in milestone payments this year as expected. (BioWorld Today)

A Phase III failure of Nexavar in advanced melanoma thumped Onyx Pharmaceuticals Inc.'s stock by more than 30 percent Monday. (BioWorld Today)

A loss of exclusivity, strong competition and a changing market led Pfizer Inc. to cut its U.S. sales force by 20 percent last week, yet analysts say the move should have little impact - if any - on the biotech community. (BioWorld Today)

It is the opinion of many biotech executives that the best time to raise money is when you don't need it. (BioWorld Today)

Licensing a pulmonary arterial hypertension program from a Swiss company, Biogen Idec Inc. has stepped into a new therapeutic area to address a frequently undiagnosed disease that may affect up to 200,000 people worldwide. (BioWorld Today)